The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with resectable NSCLC.

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.

Two strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with ...

Nivolumab plus ipilimumab can provide long-term benefits to patients with advanced melanoma, according to a 10-year update of the CheckMate 067 trial.

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...